NIH Awards Grant to TTUHSC Researcher

Project To Investigate New Therapy Targets for Rare Cancer

Magdalena Karbowniczek, M.D., Ph.D

Pulmonary lymphangioleiomyomatosis (LAM) is a rare form of cancer that affects up to eight of every one million women of reproductive age worldwide. This disease is characterized by the uncontrolled growth (proliferation) of tumor cells that are biologically similar to smooth muscle cells in the lungs, kidneys and lymphatics; these cells will spread and invade various locations throughout the body. Currently there are approximately 1,500 confirmed cases in the U.S.

The most common symptom associated with LAM is shortness of breath, especially upon exertion. In most cases, the disease progresses slowly and over time can lead to lung collapses and ultimately respiratory failure.

To better understand the role of extracellular vesicles (EV) in the spread and progression of LAM, the National Institutes of Health (NIH) recently awarded a four-year, $2.8 million grant to Magdalena Karbowniczek, M.D., Ph.D., a professor of immunotherapeutics and biotechnology at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy. Based upon the study’s progress and the availability of funds, the NIH could extend the grant to five years and approximately $3.5 million.

Magdalena Karbowniczek, M.D., Ph.D

EVs are tiny nanometer size particles released by healthy cells to “communicate” with other cells. Karbowniczek said they also are thought to facilitate cancer metastasis; however, their role in LAM has not yet been explored.

“We hope to establish EVs — and the mechanisms that control their release from [some] cells and uptake by other cells — as targets for new LAM therapy,” Karbowniczek said. “There are currently medications that target EVs that are tested in clinical trials for other cancers; therefore, if we discover that EVs are promoting LAM progression and spread, they can be repurposed for LAM.”

There are two main types of LAM: sporadic LAM, which develops spontaneously, and LAM associated with tuberous sclerosis complex, an inheritable genetic condition manifesting with multiple tumors in different organs. The therapeutic options for LAM patients are very limited, as the only drug currently available for LAM is everolimus, an analog of rapamycin that in some patients can slow the progress of disease. However, everolimus does not stop lung destruction, and the disease relapses once treatment ends.

“We hope that through studies funded by this grant we will be able to identify new therapeutic targets, and that knowledge gained through this work will be instrumental for the development of new therapies for  LAM patients,” Karbowniczek added.

The project is a collaboration with the University of Cincinnati (UC); Jane Yu, Ph.D., a professor of internal medicine at the UC College of Medicine also is a co-principal investigator (PI) on this grant. Karbowniczek and Yu have collaborated for almost 20 years after initially investigating LAM together as postdoctoral trainees under Lisa Henske, M.D., a world-renowned LAM expert at Fox Chase Cancer Center in Philadelphia.

TTUHSC co-investigators for the grant include Irene La-Beck, Pharm.D., and Maciej Markiewski, M.D., Ph.D. UC co-investigator Frank X. McCormack, M.D., who leads international randomized trials for LAM, also will provide expertise necessary for these studies.

“This multi-PI grant unifies [our] expertise in LAM again and formalizes a long-lasting collaboration for the benefit of LAM patients,” Karbowniczek said.

Related Stories


Taking a Big Step in Structural Biology

Luis Cuello, Ph.D., a professor in the Department of Cell Physiology and Molecular Biophysics at the TTUHSC School of Medicine, was awarded a five-year R35 MIRA grant from the National Institutes of Health (NIH).


TTUHSC’s Garrison Institute on Aging Program Supports Dementia Patients, Family Caregivers

Recent estimates say that more than 400,000 people in Texas are living with ADRD, and more than 1.5 million unpaid family members and friends are serving as informal caregivers for these ADRD patients.


TTU System Health Policy and Public Health Think Tank Hosted First West Texas Health Disparities Research Symposium

The inaugural West Texas Health Disparities Research Symposium marks the largest event resulting from the work of the TTU System Health Policy and Public Health Think Tank.

Recent Stories


Willed Body Memorial Service Honors Those Who Donated

On Memorial Day each May, a service is conducted to pay respect to the Willed Body Program donors and their families.


Motivation From the Heart

While the TTU System aimed to cast a spotlight on these individuals and their work, the honorees chose to cast that light onto others, sharing their humble gratitude toward those who helped, guided and inspired them.

Campus Life

TTUHSC Honors Class of 2023 at Commencement Ceremonies

TTUHSC hosted commencement ceremonies for its 1,669-member Class of 2023.